{
  "id": 20871407,
  "title": "BioVersys Reports Results From Phase 2a ENABLE Study",
  "url": "https://urgent.news/2026/11/20/bioversys-reports-results-from-phase-2a-enable-study",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T07:02:01.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/bioversys-reports-results-phase-2a-enable-study"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - BioVersys AG (BIOV.SW) announced results from the Phase 2a ENABLE study of alpibectir in combination with ethionamide or AlpE in patients with newly diagnosed drug-sensitive pulmonary tuberculosis. The phase 2a ENABLE study showed early bactericidal activity in all re",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}